


# **Controversies in the management of laryngeal and hypopharyngeal advanced tumors**



**Rogério A. Dedivitis**

Full Professor

Chair, Group of Laryngeal and Hypopharyngeal Cancer

Dept. HNS, Hospital das Clínicas, University of São Paulo School of Medicine

Chair, Departaments HNS, Hospital Ana Costa and Santa Casa da Misericórdia,  
Santos


**Advanced laryngeal / hypopharyngeal tumors**

# **Introduction**


## **Advanced laryngeal / hypopharyngeal tumors**

### **Introduction**

- ✓ **laryngeal cancer: the 2<sup>nd</sup> more common in H&N**
- ✓ **CS I / II: 63.6%**
- ✓ **CS III / IV: 37.5%**
- ✓ **supraglottis: 55.8% in CS III / IV**
- ✓ **glottis: 16.3% in CS III / IV**
- ✓ **standard treatment: surgery + adjuvant RXT**
- ✓ **TL: required for all advanced glottic tumors and > 70% of supraglottic tu**
- ✓ **consequence: definitive stoma**



## Advanced laryngeal / hypopharyngeal tumors



- ✓  $n = 332$
- ✓ 2-year survival = 68% for both groups ( $p = 0.9846$ )
- ✓ CRT group: > local recurrence and < distant metastasis
- ✓ **laryngeal preservation: 66%**
- ✓ **criticism: the lack of exclusive RXT branch**

Wolf et al., 1991

## Advanced laryngeal / hypopharyngeal tumors

V.A. Laryngeal Cancer Study Group, 1991







Figure 1. Overall Survival of 332 Patients Randomly Assigned



## Advanced laryngeal / hypopharyngeal tumors

### Sequential X concomitant CRT

- ✓ 3 weekly cycles, cis 100mg/m<sup>2</sup> + 5-FU + RXT 70Gy X cis 60mg/m<sup>2</sup> + 5-FU concomitant to RXT, 7-8 weeks
- ✓ 107 pts. in each group, resectable, randomized
- ✓ severe toxicity similar in both groups
- ✓ mucositis and nephropathy: worse in concomitant approach





Taylor et al., 1994

# Advanced laryngeal / hypopharyngeal tumors

## RTOG 91-11

- ✓ advanced laryngeal tumor, randomized
- ✓ RXT X cis and 5-FU sequential to RXT X cis and 5-FU concomitant to RXT
- ✓ intact larynx after 2 years: 70% X 77% X 88%
- ✓ CRT: < distant metastasis, similar survival rates





Forastiere et al., 2003

## Advanced laryngeal / hypopharyngeal tumors

### Mortality increase

- ✓ 128,426 cases of laryngeal cancer, 1985 – 2001, NCDB
- ✓ related to changes of the therapeutic approach
- ✓ 80/90 decades: < survival, > CRT, < surgery


Hoffman et al., 2006



## Advanced laryngeal / hypopharyngeal tumors

### Treatment X survival for T4 laryngeal cancer



- ✓ n = 451
- ✓ Gourin et al., 2009



## Advanced laryngeal / hypopharyngeal tumors

### TAX 324

- ✓ TPF induction CRT X PF, randomized, n = 501 CS III / IV
- ✓ RXT + Carboplatin
- ✓ toxicity: neutropenia




Posner et al., 2007

# Advanced laryngeal / hypopharyngeal tumors

NCCN


## ✓ glottic tumors



# Advanced laryngeal / hypopharyngeal tumors

NCCN

## ✓ glottic tumors



**Advanced laryngeal / hypopharyngeal tumors**

**Partial laryngectomy feasible?**

## Advanced laryngeal / hypopharyngeal tumors SCL



- ✓ n = 19; aspirative pneumonia = 3; laryngeal sinechia = 2; local recurrence = 4

Schröder et al., 2003

- ✓ n = 46; 44 decanulization (average = 20/41 dias); NET removal: 21/40 dias; 2 local recurrences salvaged; 3-year global survival rate = 95.7%

Akbas & Demireller, 2005

- ✓ n = 41



Castro et al., 2010

## Advanced laryngeal / hypopharyngeal tumors

### Subtotal laryngectomy

✓ 399 SCL; 70 STL

SCL		
CHEP	98/103	95.1
CHEP + A	165/169	97.6
CHP	33/36	91.7
CHP + A	86/91	94.5
STL		
THEP	10/11	90.9
THEP + A	41/51	80.4
THP	—	—
THP + A	5/8	62.5



Rizzotto et al., 2012

## Advanced laryngeal / hypopharyngeal tumors

✓ partial, not  
conservative!



D' Cruz et al., 2012

Study	Pts with sat SO (of total pts)	
	n	%
Singh & Hardcastle <sup>12</sup>	4/4	100
Hoasjoe et al. <sup>24</sup>	11/11	100
Desanto et al. <sup>25</sup>	29/39	74
Pearson et al. <sup>4</sup>	7/7	100
Levine et al. <sup>26</sup>	9/11	82
Han et al. <sup>21</sup>	27/28	96.4
Chandrachud et al. <sup>27</sup>	11/11	100
Su & Hwang <sup>28</sup>	18/21	86
Shan <sup>29</sup>	10/10	100
Tang et al. <sup>20</sup>	12/14	85.7
Suits et al. <sup>30</sup>	30/39	76
Shenoy et al. <sup>31</sup>	23/29	79.3
Thakar et al. <sup>11</sup>	23/28	82
Shenoy et al. <sup>15</sup>	44/54	81
Cakli et al. <sup>32</sup>	19/23	82.6
Andrade et al. <sup>14</sup>	35/42	83.3
Maamoun et al. <sup>16</sup>	31/38	81.6
Qi et al. <sup>18</sup>	10/12	83.3
Aslan et al. <sup>9</sup>	90/127	70.8
Pearson et al. <sup>8</sup>	191/225	85
Kavabata et al. <sup>17</sup>	12/15	80
Bernáldez et al. <sup>23</sup>	61/79	77.2
Su <sup>33</sup>	50/66	76
Pradhan et al. <sup>34</sup>	135/150	90

## Advanced laryngeal / hypopharyngeal tumors



**Advanced laryngeal / hypopharyngeal tumors**

**T4a / T4b tumors**

## **Advanced laryngeal / hypopharyngeal tumors**

---

**TABLE I.**  
Strategies for Vocal Rehabilitation of Laryngectomized Patients.




---

- A. Esophageal voice
  - B. Surgical methods
    - a. Mucosal or skin fistula directing air from lungs to upper esophagus and pharynx
    - b. Pharyngo-cutaneous fistula, connected to tracheostome via external prosthetic valve
    - c. Implantation of unidirectional prosthetic valve into fistula between trachea and upper esophagus or pharynx
    - d. “Near-total” resection of larynx, with creation of vocal shunt
  - C. Mechanical generators of acoustic vibrations
    - a. External electric generators
    - b. Internal electric generators
    - c. Pneumatic generators
-


## Advanced laryngeal / hypopharyngeal tumors

TEP

- ✓ Singer & Blom, 1980



## Advanced laryngeal / hypopharyngeal tumors





## Advanced laryngeal / hypopharyngeal tumors



# Advanced laryngeal / hypopharyngeal tumors TEP

Voices spectrography



# Advanced laryngeal / hypopharyngeal tumors

## Voice failure factors

- ✓ **patient's factors**
- ✓ **prosthesis factors**
- ✓ **tumor and treatment factors**

Bozec et al., 2010

Potential explicatory factors	Number of patients (n = 15)
Neurological and/or psychological impairment	3
Bad compliance and lack of motivation for speech reeducation	3
Poor respiratory function with incoercible cough and expectoration when using speech valve	2
Local tumor recurrence in the 3 postoperative months	2
Death not associated with tumor recurrence in the 3 postoperative months	2
Repeated granulation and obstruction of the tracheoesophageal fistula posterior aspect	2
Extensive mandibular radionecrosis with complete trismus	1

## **Advanced laryngeal / hypopharyngeal tumors**

### **Dysphagia**


- ✓ **videofluoroscopic assessment**
  - ✓ 26 pts. (12 TL and 14 TPL)
  - ✓ 61.5% no complaints
  - ✓ 84% dysphagia
    - ✓ 42% increase oral transit time
    - ✓ 54% base of tongue stasis
    - ✓ 73% increase pharynx transit time
    - ✓ 58% suggestive of decreasing of pharynx motility

**Salgado et al., 2006**


## Advanced laryngeal / hypopharyngeal tumors

### Swallowing videofluoroscopy


- ✓ total laryngectomees



stenosis







cricopharyngeous bar



pseudovallecula

## Advanced laryngeal / hypopharyngeal tumors      Robotic TL



Lawson et al., 2012

**Advanced laryngeal / hypopharyngeal tumors**

**T3 tumors,  
candidates to TL**

## **Advanced laryngeal / hypopharyngeal tumors**

### **Combined treatment**

- ✓ **functional outcome:**
  - ✓ worse dysphagia
  - ✓ better voice X PL / TL

Hutcheson & Lewin, 2012

- ✓ **difficult recurrence detection**
- ✓ **late detection: < salvage surgery**
- ✓ **deeper biopsy under general anesthesia**
- ✓ **surgical salvage: initial or post-protocol margins?**
- ✓ **necessity of first lesion documentation**
- ✓ **image methods limitation (CT, MRI, PET-CT)**
- ✓ **evaluation after 6 to 8 weeks (< mucositis)**

## **Advanced laryngeal / hypopharyngeal tumors**

### **Chemoradiation**

- ✓ **high incidence of acute toxicity**
- ✓ **long term functional sequelae, significant pharyngeal / esophageal edema / stenosis**
- ✓ **salvage TL: > PCF / complications**
- ✓ **higher cost**
- ✓ **aspiration among symptomatic pts.: 24% to 31%**  
*Goguen et al., 2006; Caudell et al., 2009*
- ✓ **aspiration among all pts. 30% to 62%**  
*Eisbruch et al., 2002; Agarwal et al., 2011*
- ✓ **addition of Cetuximab**
  - ✓ **well tolerated / promising results**
  - ✓ **phase II**

*Suntharaligan et al., 2012*

## **Advanced laryngeal / hypopharyngeal tumors**



**Advanced laryngeal / hypopharyngeal tumors**

# **Conclusion**


## Advanced laryngeal / hypopharyngeal tumors



X



X



## Biases

- ✓ anatomical preservation ≠ functional pres.
- ✓ RTOG 91-11: laryngectomy-free survival
- ✓ VA: > ratio of salvage TL among T4 tumors  
Hinerman et al., 2002
- ✓ > 70 y, previous tracheotomy, gastric tube, pneumonia / aspiration: excluded from preservation protocols

Léfèvre & Ang, 2009 ; Pignon et al., 2009



## **Advanced laryngeal / hypopharyngeal tumors**

**QoL just when there is no survival advantage??**

